Description
The VLS Tirzepatide 20mg Pen is a dual-receptor GLP-1/GIP agonist designed to support weight management and metabolic research. By regulating appetite, energy balance, and blood sugar, this peptide helps reduce cravings and facilitates controlled study of weight-management pathways. The pre-filled pen provides weekly precision dosing and is suitable for structured research protocols or educational studies.
Key Research Benefits
- Supports investigation of appetite control and satiety signaling
- Facilitates studies on energy-balance and metabolic regulation
- Can assist in research on weight-management interventions
- Convenient weekly dosing for reproducible laboratory or observational studies
- Pre-filled pen ensures accuracy and ease of use
Dosing Protocol
A conservative escalation schedule is often used in research to minimize adverse effects:
- Week 1–4: 2.5mg weekly (starting dose)
- Week 5–8: 5mg weekly
- Optional escalation: 7.5mg → 10mg → up to 15mg weekly (as tolerated/required)
Administration Guidelines:
- Inject subcutaneously into the abdomen, thigh, or upper arm
- Do not inject intramuscularly or intravenously
- Maintain consistent weekly dosing, adjusting only if ≥2 days since the last dose
- Rotate injection sites with each administration
- Do not share pen between individuals
- Follow applicable research safety and handling protocols
Storage & Handling:
- Keep refrigerated
- Dispose of used needles safely
- Avoid mixing with insulin in the same syringe
Shipping & Availability
- Fast, discreet shipping to UK, Europe, and USA
- Secure packaging ensures product integrity
- Suitable for laboratory, research, or educational study purposes
